Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.60 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | CCNH | P51946 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | EGFR | P00533 | 9/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240956 | 0.93 | JAK3 (0.54) | JAK3MAPK3BTKEGFRITK | |
| SCHEMBL30931289 | 0.93 | JAK3 (0.54) | JAK3MAPK3BTKEGFRITK | |
| SCHEMBL27240898 | 0.91 | JAK3 (0.50) | JAK3JAK2BTKEGFRITK | |
| SCHEMBL26979886 | 0.90 | JAK3 (0.52) | JAK3MAPK3BTKEGFRITK | |
| SCHEMBL29929286 | 0.90 | JAK3 (0.52) | JAK3MAPK3BTKEGFRITK | |
| SCHEMBL27240910 | 0.90 | JAK3 (0.49) | JAK3CDK7CCNHJAK2JAK1 | |
| SCHEMBL27240786 | 0.89 | JAK3 (0.49) | JAK3CDK7CCNHJAK2JAK1 | |
| SCHEMBL27240819 | 0.87 | JAK3 (0.45) | JAK3CDK7CCNHJAK2JAK1 | |
| SCHEMBL27240869 | 0.87 | JAK3 (0.45) | JAK3CDK7CCNHJAK2JAK1 | |
| SCHEMBL27240814 | 0.87 | JAK3 (0.59) | JAK3JAK2JAK1TTKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | claimed |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | JAK3 1800/4885CDK7 312/4885CCNH 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.